Craig A. Collard - 30 Jan 2026 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role: Chief Executive Officer, Director
Signature: /s/ Kathryn Lester Attorney-in-fact for Craig Collard
Issuer symbol: HRTX
Transactions as of: 30 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2026, 10:00:14 UTC
Previous filing: 20 Jan 2026
Next filing: 03 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Collard Craig A	Chief Executive Officer, Director	100 REGENCY FOREST DRIVE, SUITE 300, CARY	/s/ Kathryn Lester Attorney-in-fact for Craig Collard	03 Feb 2026	0001363558

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HRTX	Restricted Stock Units	Award	$0	+800,337		$0.000000	800,337	30 Jan 2026	Common Stock	800,337		Direct	F1, F2
transaction	HRTX	Performance Stock Units	Award	$0	+800,336		$0.000000	800,336	30 Jan 2026	Common Stock	800,336		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.
F3	Performance stock units ("PSUs") convert into common stock on a one-for-one basis.
F4	On January 30, 2026, the Reporting Person was granted 800,336 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.